Media coverage about Cogentix Medical (NASDAQ:CGNT) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cogentix Medical earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.7437841478894 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have impacted Accern’s scoring:

Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Cogentix Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. JMP Securities assumed coverage on shares of Cogentix Medical in a research note on Friday. They issued an “outperform” rating and a $5.00 target price for the company.

Cogentix Medical (NASDAQ:CGNT) traded up 8.74% during trading on Friday, hitting $3.11. 335,179 shares of the stock traded hands. Cogentix Medical has a 52-week low of $1.37 and a 52-week high of $3.26. The company’s market cap is $189.44 million. The firm has a 50-day moving average price of $2.51 and a 200 day moving average price of $1.98.

Cogentix Medical (NASDAQ:CGNT) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Cogentix Medical had a negative net margin of 35.88% and a negative return on equity of 13.83%. The firm had revenue of $14.06 million for the quarter, compared to analysts’ expectations of $13.90 million. On average, equities analysts expect that Cogentix Medical will post ($0.03) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/cogentix-medical-cgnt-earns-media-impact-score-of-0-11/1615523.html.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Insider Buying and Selling by Quarter for Cogentix Medical (NASDAQ:CGNT)

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.